Please login to the form below

Not currently logged in
Email:
Password:

sickle cell disease

This page shows the latest sickle cell disease news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk pays $400m for EpiDestiny’s sickle cell drug

Novo Nordisk pays $400m for EpiDestiny’s sickle cell drug

Novo Nordisk pays $400m for EpiDestiny’ s sickle cell drug. The candidate is expected to start a phase II trial in the coming months. ... Novo Nordisk has bolstered its biopharma unit with a global licensing deal for a small-molecule drug for genetic

Latest news

More from news
Approximately 4 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    Gevokizumab plus IP for use of IL-1 beta targeting antibodies for cardiovascular disease. ... 425 (upfront 80). Calimmune (US). CSL (AU). Company acquisition. Preclinical haematopoietic stem cell therapy for sickle cell disease.

  • Deal Watch November 2016 Deal Watch November 2016

    antibody, SelG1, after the completion of a phase II study in patients with sickle cell disease (SCD). ... lead product - SelG1, anti-P-selection mAb for reduction of vaso-occlusive pain crises in patients with sickle cell.

  • Deal Watch October 2015 Deal Watch October 2015

    The collaboration between CRISPR Therapeutics and Vertex will evaluate the use of CRISPR/Cas9 in a number of diseases with defined genetic targets, including cystic fibrosis and sickle cell disease. ... 17, 200. CRISPR Therapeutics/ Vertex Pharmaceuticals

  • Pharma deals during August 2014 Pharma deals during August 2014

    It also has potential utility in treating systemic sclerosis-related Interstitial Lung Disease. ... It is currently being investigated as the sole stem cell source in a phase I/II study to treat haematological malignancies such as leukaemia and lymphoma

  • Pharma deals during July 2014 Pharma deals during July 2014

    Cosmo Technologies is an Irish-domiciled subsidiary of Italian-based Cosmo Pharmaceuticals, which has a focus in gastrointestinal disease and dermatology. ... for sickle cell disease (SCD), called Aes-103.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Cellerant appoints William Reed as VP clinical development Cellerant appoints William Reed as VP clinical development

    He has previous experience in treatments for blood conditions, spending time as director, clinical research and medical affairs at Cerus, where he worked on a programme for sickle cell disease. ... transplantation, leukaemia and acute radiation syndrome

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics